Phase-Appropriate Plasmid DNA Manufacturing for Cell & Gene
Therapy
Download the Aldevron Article
| region | na1 |
| portalId | 1769030 |
| formId | 9d3608e8-4663-469a-a457-b159c2fbbd2b |
| target | services-hubspot-form |
| redirectUrl | https://www.aldevron.com/thank-you/whitepaper-empowering-future-cell-gene-therapy |
Empowering the Future of Cell and Gene Therapy
Explore how Aldevron’s GMP-Source™ and Small-Scale cGMP services provide scalable, cost-effective, and regulatory-ready plasmid DNA manufacturing solutions tailored to early-stage clinical trials.
What You'll Learn
- The difference between GMP-Source™ and Small-Scale cGMP
- How phase-appropriate manufacturing accelerates timelines and reduces costs
- Why Aldevron’s model supports seamless transition to full cGMP
- Strategic insights for early-stage CGT developers navigating regulatory complexity
Why It Matters
Cell and gene therapy developers face unique challenges in early-stage manufacturing. Our approach helps you:
- Avoid costly delays and inefficiencies
- Maintain regulatory confidence
- Scale with precision and flexibility
- Leverage 20+ years of manufacturing expertise